Search
Research
Novel oncogenic PDGFRA mutations in pediatric high-grade gliomasThe outcome for children with high-grade gliomas (HGG) remains dismal, with a 2-year survival rate of only 10% to 30%.
Research
Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemiaDrug-resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death from disease in children.
Research
Family history of cancer and the risk of childhood brain tumors: a pooled analysis of the ESCALE and ESTELLE studies (SFCE)Our findings support the hypothesis of a familial susceptibility of childhood brain tumors, not due to being a known neurofibromatosis carrier
Research
Bacillus Cereus Bacteremia and Multiple Brain Abscesses During Acute Lymphoblastic Leukemia Induction TherapyBacillus cereus can cause serious infections in immunosuppressed patients. This population may be susceptible to B. cereus pneumonia, bacteremia, cellulitis,...
Research
Home pesticide exposures and risk of childhood leukemia: Findings from the childhood leukemia international consortiumIn this investigation, the authors found an association between home pesticide exposure before birth and during a child's early years and acute lymphoblastic...
Research
Challenges posed by COVID-19 to children with cancerDevelopment of standardised guidance by national and regional authorities for reducing the risk of SARS-CoV-2 transmission to children with cancer
The WA Kids Cancer Centre has a suite of world-leading research projects to unlock new treatments for childhood cancers.
Research
KMT2A-rearranged acute lymphoblastic leukaemiaKMT2A-rearranged acute lymphoblastic leukaemia (ALL) represents a high risk subtype of childhood ALL. Historical treatment strategies have comprised of intensification with conventional chemotherapy. However, outcomes have remained consistently poor compared to the advances that have been seen for other ALL subtypes, particularly for infants diagnosed before their first birthday
Research
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene FusionsTropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients.
Research
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockadeW. Joost Ben Lizeth Rachael Tao Omar Lesterhuis Wylie Orozco Morales Zemek Wang Elaskalani BSc PhD BSc, MSc, PhD BSc (Hons), PhD PhD BSc, MSc, PhD